Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

Joseph I. Clark, Michael K.K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, Lionel D. Lewis, John H. Stewart, Ulka Vaishampayan, Brendan Curti, René Gonzalez, Jose Lutzky, Venkatesh Rudraptna, Lee D Cranmer, Joanne M Jeter, Ralph J. Hauke, Gerald Miletello, Mohammed M. Milhem, Asim AminJohn M. Richart, Mayer Fishman, Sigrun Hallmeyer, Sapna P. Patel, Peter Van Veldhuizen, Neeraj Agarwal, Bret Taback, Jonathan S. Treisman, Marc S. Ernstoff, Jessica C. Perritt, Hong Hua, Tharak B. Rao, Janice P. Dutcher, Sandra Aung

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Micro-Abstract ProleukinR Observational Study to Evaluate the Treatment Patterns and Clinical Response in Malignancy (PROCLAIMSM) is the largest observational clinical database of high-dose interleukin-2 (HD IL-2)-treated patients in the US. Herein, the survival and outcome for patients with renal cell carcinoma receiving HD IL-2 in sequence with targeted therapy are described. HD IL-2 has an acceptable efficacy and safety profile in current clinical practice and remains a valuable therapy for patients with renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)31-41.e4
JournalClinical Genitourinary Cancer
Volume15
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Survival Analysis
Renal Cell Carcinoma
Immunotherapy
Interleukin-2
Clinical Trials
Observational Studies
Therapeutics
Databases
Safety
Survival
Neoplasms

Keywords

  • Anti-VEGF therapy
  • Cytokine
  • Kidney cancer
  • Therapy trends
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy : An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. / Clark, Joseph I.; Wong, Michael K.K.; Kaufman, Howard L.; Daniels, Gregory A.; Morse, Michael A.; McDermott, David F.; Agarwala, Sanjiv S.; Lewis, Lionel D.; Stewart, John H.; Vaishampayan, Ulka; Curti, Brendan; Gonzalez, René; Lutzky, Jose; Rudraptna, Venkatesh; Cranmer, Lee D; Jeter, Joanne M; Hauke, Ralph J.; Miletello, Gerald; Milhem, Mohammed M.; Amin, Asim; Richart, John M.; Fishman, Mayer; Hallmeyer, Sigrun; Patel, Sapna P.; Van Veldhuizen, Peter; Agarwal, Neeraj; Taback, Bret; Treisman, Jonathan S.; Ernstoff, Marc S.; Perritt, Jessica C.; Hua, Hong; Rao, Tharak B.; Dutcher, Janice P.; Aung, Sandra.

In: Clinical Genitourinary Cancer, Vol. 15, No. 1, 01.02.2017, p. 31-41.e4.

Research output: Contribution to journalArticle

Clark, JI, Wong, MKK, Kaufman, HL, Daniels, GA, Morse, MA, McDermott, DF, Agarwala, SS, Lewis, LD, Stewart, JH, Vaishampayan, U, Curti, B, Gonzalez, R, Lutzky, J, Rudraptna, V, Cranmer, LD, Jeter, JM, Hauke, RJ, Miletello, G, Milhem, MM, Amin, A, Richart, JM, Fishman, M, Hallmeyer, S, Patel, SP, Van Veldhuizen, P, Agarwal, N, Taback, B, Treisman, JS, Ernstoff, MS, Perritt, JC, Hua, H, Rao, TB, Dutcher, JP & Aung, S 2017, 'Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM', Clinical Genitourinary Cancer, vol. 15, no. 1, pp. 31-41.e4. https://doi.org/10.1016/j.clgc.2016.10.008
Clark, Joseph I. ; Wong, Michael K.K. ; Kaufman, Howard L. ; Daniels, Gregory A. ; Morse, Michael A. ; McDermott, David F. ; Agarwala, Sanjiv S. ; Lewis, Lionel D. ; Stewart, John H. ; Vaishampayan, Ulka ; Curti, Brendan ; Gonzalez, René ; Lutzky, Jose ; Rudraptna, Venkatesh ; Cranmer, Lee D ; Jeter, Joanne M ; Hauke, Ralph J. ; Miletello, Gerald ; Milhem, Mohammed M. ; Amin, Asim ; Richart, John M. ; Fishman, Mayer ; Hallmeyer, Sigrun ; Patel, Sapna P. ; Van Veldhuizen, Peter ; Agarwal, Neeraj ; Taback, Bret ; Treisman, Jonathan S. ; Ernstoff, Marc S. ; Perritt, Jessica C. ; Hua, Hong ; Rao, Tharak B. ; Dutcher, Janice P. ; Aung, Sandra. / Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy : An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. In: Clinical Genitourinary Cancer. 2017 ; Vol. 15, No. 1. pp. 31-41.e4.
@article{d6fec9c8410149fb9b5ce6a3ae5d3309,
title = "Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM",
abstract = "Micro-Abstract ProleukinR Observational Study to Evaluate the Treatment Patterns and Clinical Response in Malignancy (PROCLAIMSM) is the largest observational clinical database of high-dose interleukin-2 (HD IL-2)-treated patients in the US. Herein, the survival and outcome for patients with renal cell carcinoma receiving HD IL-2 in sequence with targeted therapy are described. HD IL-2 has an acceptable efficacy and safety profile in current clinical practice and remains a valuable therapy for patients with renal cell carcinoma.",
keywords = "Anti-VEGF therapy, Cytokine, Kidney cancer, Therapy trends, Toxicity",
author = "Clark, {Joseph I.} and Wong, {Michael K.K.} and Kaufman, {Howard L.} and Daniels, {Gregory A.} and Morse, {Michael A.} and McDermott, {David F.} and Agarwala, {Sanjiv S.} and Lewis, {Lionel D.} and Stewart, {John H.} and Ulka Vaishampayan and Brendan Curti and Ren{\'e} Gonzalez and Jose Lutzky and Venkatesh Rudraptna and Cranmer, {Lee D} and Jeter, {Joanne M} and Hauke, {Ralph J.} and Gerald Miletello and Milhem, {Mohammed M.} and Asim Amin and Richart, {John M.} and Mayer Fishman and Sigrun Hallmeyer and Patel, {Sapna P.} and {Van Veldhuizen}, Peter and Neeraj Agarwal and Bret Taback and Treisman, {Jonathan S.} and Ernstoff, {Marc S.} and Perritt, {Jessica C.} and Hong Hua and Rao, {Tharak B.} and Dutcher, {Janice P.} and Sandra Aung",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.clgc.2016.10.008",
language = "English (US)",
volume = "15",
pages = "31--41.e4",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy

T2 - An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

AU - Clark, Joseph I.

AU - Wong, Michael K.K.

AU - Kaufman, Howard L.

AU - Daniels, Gregory A.

AU - Morse, Michael A.

AU - McDermott, David F.

AU - Agarwala, Sanjiv S.

AU - Lewis, Lionel D.

AU - Stewart, John H.

AU - Vaishampayan, Ulka

AU - Curti, Brendan

AU - Gonzalez, René

AU - Lutzky, Jose

AU - Rudraptna, Venkatesh

AU - Cranmer, Lee D

AU - Jeter, Joanne M

AU - Hauke, Ralph J.

AU - Miletello, Gerald

AU - Milhem, Mohammed M.

AU - Amin, Asim

AU - Richart, John M.

AU - Fishman, Mayer

AU - Hallmeyer, Sigrun

AU - Patel, Sapna P.

AU - Van Veldhuizen, Peter

AU - Agarwal, Neeraj

AU - Taback, Bret

AU - Treisman, Jonathan S.

AU - Ernstoff, Marc S.

AU - Perritt, Jessica C.

AU - Hua, Hong

AU - Rao, Tharak B.

AU - Dutcher, Janice P.

AU - Aung, Sandra

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Micro-Abstract ProleukinR Observational Study to Evaluate the Treatment Patterns and Clinical Response in Malignancy (PROCLAIMSM) is the largest observational clinical database of high-dose interleukin-2 (HD IL-2)-treated patients in the US. Herein, the survival and outcome for patients with renal cell carcinoma receiving HD IL-2 in sequence with targeted therapy are described. HD IL-2 has an acceptable efficacy and safety profile in current clinical practice and remains a valuable therapy for patients with renal cell carcinoma.

AB - Micro-Abstract ProleukinR Observational Study to Evaluate the Treatment Patterns and Clinical Response in Malignancy (PROCLAIMSM) is the largest observational clinical database of high-dose interleukin-2 (HD IL-2)-treated patients in the US. Herein, the survival and outcome for patients with renal cell carcinoma receiving HD IL-2 in sequence with targeted therapy are described. HD IL-2 has an acceptable efficacy and safety profile in current clinical practice and remains a valuable therapy for patients with renal cell carcinoma.

KW - Anti-VEGF therapy

KW - Cytokine

KW - Kidney cancer

KW - Therapy trends

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85007451708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007451708&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2016.10.008

DO - 10.1016/j.clgc.2016.10.008

M3 - Article

C2 - 27916626

AN - SCOPUS:85007451708

VL - 15

SP - 31-41.e4

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -